Clinical Trials
25 trialsNCT04833582 2026-04-03
A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Completed
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT04154189 2024-07-22
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
Eisai Inc.
Phase 2 Completed
NCT05093322 2024-06-07
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT02432274 2023-07-11
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
Eisai Inc.
Phase 1/2 Completed
NCT02982941 2022-02-08
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
MacroGenics
Phase 1 Completed
NCT01987102 2020-09-25
Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.
Isofol Medical AB
Phase 1/2 Completed
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT01962103 2019-12-27
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Celgene
Phase 1/2 Completed
NCT01650090 2019-08-07
Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma
Eleison Pharmaceuticals LLC.
Phase 2 Completed
NCT00102531 2017-08-01
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
Insmed Incorporated
Phase 1/2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT02383901 2016-09-05
FORTO
Isofol Medical AB
Completed
NCT01169584 2016-01-21
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
SillaJen, Inc.
Phase 1 Completed
NCT00413075 2015-07-08
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Phase 1 Completed
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT00093080 2015-02-13
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00503295 2014-10-02
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Oncolytics Biotech
Phase 2 Completed
NCT00631631 2014-05-14
Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma
Millennium Pharmaceuticals, Inc.
Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00523419 2011-06-28
Chemotherapy for Patients With Osteosarcoma
Eli Lilly and Company
Phase 2 Completed
NCT00572130 2011-06-10
Phase II Study of Intravenous Rexin-G in Osteosarcoma
Epeius Biotechnologies
Phase 2 Completed
NCT00520936 2011-02-25
A Study of Pemetrexed in Children With Recurrent Cancer
Eli Lilly and Company
Phase 2 Completed